Titan, Pharmaceuticals, Inc

Spheramine for Parkinson receives FDA fast track designation

Published in Hospital Business Week, August 15th, 2004

Titan Pharmaceuticals, Inc. (TTP) announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for Spheramine for the treatment of advanced Parkinson disease.

The fast track program is designed by FDA to facilitate the development and expedite the review of drug candidates that demonstrate the potential to treat serious or life-threatening diseases and address unmet medical needs. Spheramine is a cell therapy product initially being developed for the treatment of advanced Parkinson patients who are not satisfactorily controlled with current medications.

Spheramine consists of normal, human retinal pigment epithelial...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hospital Business Week

Source: Hospital Business Week (2004-08-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry